Oragenics Inc. (NYSE American: OGEN), a clinical-stage biotechnology company focused on brain-targeted therapeutics, announced it has regained full compliance with NYSE American listing standards. The company also reported significant progress in the third quarter of 2025, including the establishment of clinical infrastructure in Australia and preparations for its first-ever Phase IIa trial of ONP-002, a potential treatment for concussion.
In addition to advancing its lead candidate, Oragenics launched a strategic collaboration with Receptor.AI to expand its neurological therapeutics pipeline using artificial intelligence. The collaboration aims to identify and validate next-generation candidates for conditions such as Parkinson's, Alzheimer's, PTSD, and anxiety. “We’re not building a one-drug company—we’re building a neurological therapeutics platform,” said CEO Janet Huffman.
ONP-002 is being developed as a potential first FDA-approved treatment for concussion, utilizing Oragenics' proprietary intranasal delivery technology designed to enable targeted, non-invasive therapeutics for brain-related conditions. The company believes this platform could open pathways to address neurodegenerative diseases and central nervous system disorders.
The company's progress and strategic moves underscore its commitment to revolutionizing neurological care. For more details, the full press release is available at https://ibn.fm/rLGMC. Latest news and updates on OGEN can be found in the company's newsroom at https://ibn.fm/OGEN.
